Loading...

PE anti-mouse CD62L Antibody

Pricing & Availability
Clone
MEL-14 (See other available formats)
Regulatory Status
RUO
Other Names
L-selectin, LECAM-1, Ly-22, LAM-1, MEL-14
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
MEL-14_PE_090707
C57BL/6 mouse splenocytes stained with MEL-14 PE
  • MEL-14_PE_090707
    C57BL/6 mouse splenocytes stained with MEL-14 PE
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
104407 50 µg 88€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
104408 200 µg 235€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD62L is a 74-95 kD glycoprotein also known as L-selectin, LECAM-1, Ly-22, LAM-1, and MEL-14. It is a member of the selectin family and is expressed on the majority of B and naïve T cells, a subset of memory T cells, monocytes, granulocytes, most thymocytes, and a subset of NK cells. CD62L is important in lymphocyte homing to high endothelial venules (HEV) in peripheral lymph nodes and leukocyte "rolling" on activated endothelium. CD62L also contributes to neutrophil emigration at inflammatory sites. CD62L is rapidly shed from lymphocytes and neutrophils upon cellular activation and the expression levels of CD62L (in conjunction with other markers) have been used to distinguish naïve, effector, and memory T cells. CD62L has been reported to interact with CD34, GlyCAM-1, and MAdCAM-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
C3H/eb mouse B lymphoma 38C-13
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation1-3, complement-dependent cytotoxicity4, in vivo and in vitro blocking of adhesion1-3,5, and immunohistochemical staining of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections6. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 104457-104462).

Application References

(PubMed link indicates BioLegend citation)
  1. Gallatin WM, et al. 1983. Nature 304:30. (IP, Block)
  2. Siegelman MH, et al. 1990. Cell 61:611. (IP, Block)
  3. Lewinsohn DM, et al. 1987. J. Immunol. 138:4313. (IP, Block)
  4. Iwabuchi K, et al. 1991. Immunobiology 182:161. (CMCD)
  5. Pizcueta P, et al. 1994. Am. J. Pathol. 145:461.
  6. Reichert RA, et al. 1986. J. Immunol. 136:3535. (IHC, FC)
  7. Olver S, et al. 2006. Cancer Res. 66:571.
  8. Fukushima A, et al. 2006. Invest. Ophthalmol. Vis. Sci. 47:657. PubMed
  9. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719. (FC) PubMed
  10. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed
  11. Lee JW, et al. 2006. Nature Immunol. 8:181.
  12. Shigeta A, et al. 2008. Blood 112:4915 (FC) PubMed
  13. de Vries VC, et al. 2009. Am. J. Transplant. 9:2270 PubMed
Product Citations
  1. Laura C Burzynski et al. 2019. Immunity. 50(4):1033-1042 . PubMed
  2. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  3. Li B, Schmidt N 2016. PLoS One. 11: 0162427. PubMed
  4. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  5. Chen N, et al. 2021. Front Immunol. 12:756423. PubMed
  6. Pani F, et al. 2021. Endocrinology. 162:. PubMed
  7. Koenig A, et al. 2022. Front Immunol. 12:791100. PubMed
  8. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  9. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
  10. VanDyke D, et al. 2022. Cell Rep. 41:111478. PubMed
  11. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
  12. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
  13. Gon Y, et al. 2023. PLoS One. 18:e0279389. PubMed
  14. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  15. Yeh CH, et al. 2022. Immunity. 55:272. PubMed
  16. Kodali S, et al. 2022. J Immunol. 208:1085. PubMed
  17. Du J, et al. 2022. Sci Immunol. 7:eabo5407. PubMed
  18. Wang M, et al. 2022. Adv Sci (Weinh). 9:e2202914. PubMed
  19. Zhu C, et al. 2022. Chemotherapy. 67:211. PubMed
  20. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  21. Feng X, et al. 2023. Nat Commun. 14:3208. PubMed
  22. Song Y, et al. 2020. Front Immunol. 11:558143. PubMed
  23. Yu Y, et al. 2022. iScience. 25:105004. PubMed
  24. Ren S, et al. 2019. Oncol Rep. 41:1509. PubMed
  25. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  26. MacDonald K, et al. 2014. J Immunol. 192:3180. PubMed
  27. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 5:64. PubMed
  28. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  29. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  30. Duan Q, et al. 2021. Front Cell Dev Biol. 9:761193. PubMed
  31. Sawada J, et al. 2021. Am J Pathol. 191:396. PubMed
  32. Hamasato E, et al. 2014. Brain Behav Immun. 11:109. PubMed
  33. Zhao J, et al. 2019. Nat Commun. 10:899. PubMed
  34. García Nores GD, et al. 2018. Nat Commun. 9:1970. PubMed
  35. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  36. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  37. Ontiveros-Padilla L, et al. 2021. Microorganisms. 9:. PubMed
  38. Stewart JM, et al. 2020. ACS Biomater Sci Eng. 6:5941. PubMed
  39. Hojo MA, et al. 2019. Nat Commun. 2.224305556. PubMed
  40. Hiramoto T, et al. 2018. Mol Ther. 26:1255. PubMed
  41. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  42. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  43. Wang J, et al. 2021. Nat Commun. 12:6198. PubMed
  44. Lu X, et al. 2020. Sci Transl Med. 12:. PubMed
  45. Akazawa S, et al. 2021. Diabetologia. 64:878. PubMed
  46. Ng SS, et al. 2020. Nat Immunol. 21:1205. PubMed
  47. Coquery C, et al. 2014. PLoS One. 9:102284. PubMed
  48. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
  49. Trefzer A, et al. 2021. Cell Reports. 34(6):108748. PubMed
  50. Green WD, et al. 2022. J Leukoc Biol. 111:147. PubMed
  51. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  52. Kyburz A, et al. 2019. J Allergy Clin Immunol. 143:1496. PubMed
  53. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  54. Simula L et al. 2018. Cell reports. 25(11):3059-3073 . PubMed
  55. Zhu X et al. 2019. Cell reports. 27(4):1205-1220 . PubMed
  56. Yang BH, et al. 2020. Cell Reports. 27(12):3629-3645.e6.. PubMed
  57. Kretschmer L, et al. 2020. Nat Commun. 0.536805556. PubMed
  58. Ma X, et al. 2020. Immunity. 53:1315. PubMed
  59. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  60. Li D, et al. 2022. Emerg Microbes Infect. 11:2248. PubMed
  61. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  62. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  63. Oliveira AC et al. 2017. eLife. 6 pii: e30883. PubMed
  64. Fernández-Orth J, et al. 2020. Eur J Immunol. . PubMed
  65. Zheng B, et al. 2021. Bioact Mater. 6:3879. PubMed
  66. Li M, et al. 2021. Br J Pharmacol. 178:2617. PubMed
  67. Van Den Eeckhout B, et al. 2020. NPJ Vaccines. 0.252777778. PubMed
  68. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
  69. Sun Y, et al. 2020. J Immunol. 205:2649. PubMed
  70. Rui J, et al. 2021. Nat Commun. 12:5074. PubMed
  71. Xu Y, et al. 2021. iScience. 24:103445. PubMed
  72. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  73. Ramanan D, et al. 2020. Cell. 181(6):1276-1290. PubMed
  74. Lee MC, et al. 2017. J Immunol. 198:3565. PubMed
  75. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  76. Geng S, et al. 2019. Sci Adv. 5:eaav2309. PubMed
  77. Bantug GR, et al. 2018. Immunity. 48:542. PubMed
  78. Angela M, et al. 2016. Nat Commun. 7:13683. PubMed
  79. Corrado M, et al. 2020. Cell Metab. 32:981. PubMed
  80. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  81. Deptuch T, et al. 2022. Sci Rep. 12:13480. PubMed
  82. Cao Y, et al. 2022. Small. 18:e2203466. PubMed
  83. Liu Y, et al. 2021. Nat Commun. 12:6831. PubMed
  84. Guo S, et al. 2021. Frontiers in Immunology. 11:614667. PubMed
  85. Olguín J, et al. 2015. Microbes Infect. 17: 586-595. PubMed
RRID
AB_313094 (BioLegend Cat. No. 104407)
AB_313094 (BioLegend Cat. No. 104408)

Antigen Details

Structure
Selectin, 95 kD (neutrophils) or 74 kD (lymphocytes)
Distribution

Subsets of B and T cells, monocytes, granulocytes, subset of NK cells

Function
Lymphocyte homing to HEV, rolling on activated endothelium
Ligand/Receptor
CD34, GlyCAM-1, MAdCAM-1
Cell Type
B cells, Granulocytes, Monocytes, Neutrophils, NK cells, T cells, Tregs
Biology Area
Cell Adhesion, Cell Biology, Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family
Adhesion Molecules, CD Molecules
Antigen References

1. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Kishimoto TK, et al. 1990. P. Natl. Acad. Sci. USA 87:2244.
3. Tedder TF, et al. 1995. J. Exp. Med. 181:2259.

Gene ID
20343 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
CD62L
Specificity Alt (DOES NOT SHOW ON TDS):
CD62L
App Abbreviation (DOES NOT SHOW ON TDS):
FC
UniProt
View information about CD62L on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 1    Revision Date: 11/30/2012

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account